FDA Logo links to FDA home page
Center for Biologics Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Biologics Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

horizontal rule
CBER links to product areas Blood Vaccines Cellular/Gene Therapy Tissue Devices
CBER links Products Industry Healthcare Reading Room Meetings What's New
horizontal rule

Substantially Equivalent 510(k) Device Information

horizontal rule

Applicant: Baxter Healthcare Corp., Round Lake, IL
510(k) number: BK980041
Product: Sepacell Pre-Storage Leukocyte Set for Red Cells
Date: 7/16/99

horizontal rule

Summary of Safety and Effectiveness

Date Summary Prepared: November 17, 1998
Trade/Proprietary Name of Device: Sepacell Pre-Storage Leukocyte Reduction Set for red Cells
Common or Usual Name of Device: Red Blood Cell Filter for Leukocyte Removal
Classification Name of Device: Microfilter, Blood Transfusion (21 CFR 880.5440)
Legally Marketed Device Under Which Substantial Equivalence is being Claimed: Sepacell Pre-Storage Leukocyte Depletion Set for Red Cells, cleared for market entry under 510(k) BK920032 on June 7, 1993.
Device Description The set contains a filter, storage container(s), And associated tubings. It can be used for pre-storage leukoreduction of red blood cell products.
Intended Use of Device: Leukocyte reduction of one unit of Red Blood Cells or Whole Blood.
Comparison of Technical Characteristics of the Device vs Predicate Device: The product is substantially equivalent to the predicate device with regard to its design, material, methods of sterilization, and intended Use. The leukoreduction processing window for one unit of Red Blood Cells is now allowed after 2 hours of refrigeration up to outdate.
Brief Discussion of Tests and Their Results Submitted in the Application: The Sepacell Pre-Storage Leukocyte Reduction Set for Red Cells with an R-500(ll) filter was evaluated in a laboratory study which measured filter performance and in vitro red cell indices when AS-1 Red Blood Cells were leukoreduced after 2 hours, 1 day, 15-20 days, and 35-42 days of refrigerated storage. The filtered product contains less than 5x106 residual WBC per unit and a post filtration RBC recovery of >85%. Acceptable RBC parameters were found in all units both at the time of post filtration and through out 42 days storage. Acceptable RBC parameters were also obtained from aliquots of leukoreduced CPDA-1 and AS-1 RBC's stored for 35 or 42 days, respectively, in 150 mL containers.
Conclusions Drawn for the in-Vitro study that demonstrate that the Device is Safe, Effective, and Performs as Well As or Better than the Predicate Device: Based on the data from this in vitro study, it is concluded that the Sepacell Pre-Storage Leukocyte Reduction Set for Red Cells is safe and effective. Leukoreduction after 2 hours of refrigeration up to out date of Red Blood Cells provides acceptable red cells for Transfusion.

 

 
horizontal rule